Imagen de Portada

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Matheus Souza, Lubna Al‐Sharif, Vanio L. J. Antunes, Shi Yin Wong, Daniel Q. Huang, Rohit Loomba
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
por: Maral Amangurbanova, et al.
Publicado: (2024)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
por: Mazen Noureddin, et al.
Publicado: (2025)

Editorial: An Important Step Towards Mastering Metabolic Dysfunction‐Associated Steatohepatitis‐Targeted Therapy in Diabetes
por: Johnny Yau‐Cheung Chang, et al.
Publicado: (2025)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
por: Donghee Kim, et al.
Publicado: (2025)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Soroor Owrangi, et al.
Publicado: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
por: Carolin V. Schneider, et al.
Publicado: (2024)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
por: Nikita Mittal, et al.
Publicado: (2024)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
por: Federica Tavaglione, et al.
Publicado: (2025)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
por: Leon A. Adams, et al.
Publicado: (2026)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
por: Luis Antonio Díaz, et al.
Publicado: (2025)

A Message From the Editors
por: Colin W. Howden, et al.
Publicado: (2024)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
por: Matheus Souza, et al.
Publicado: (2025)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
por: Selena Z. Kuo, et al.
Publicado: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
por: Luis Calzadilla Bertot, et al.
Publicado: (2025)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
por: Supachaya Sriphoosanaphan, et al.
Publicado: (2025)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
por: Carolin V. Schneider, et al.
Publicado: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
por: Samer Gawrieh, et al.
Publicado: (2024)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
por: Xiao‐Dong Zhou, et al.
Publicado: (2025)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
por: Maryam Zafer, et al.
Publicado: (2025)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
por: Bernardo de Faria Moraes, et al.
Publicado: (2026)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Stergios A. Polyzos, et al.
Publicado: (2024)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
por: Donghee Kim, et al.
Publicado: (2025)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
por: Veeral Ajmera, et al.
Publicado: (2026)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
por: Yee Hui Yeo, et al.
Publicado: (2026)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
por: Eric Lawitz, et al.
Publicado: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
por: Kaleb Tesfai, et al.
Publicado: (2026)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Shinya Yokoyama, et al.
Publicado: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
por: C. C. Mark Cheah, et al.
Publicado: (2025)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Publicado: (2025)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
por: Emily Stephenson, et al.
Publicado: (2026)

Mortality of Acute Kidney Injury in Cirrhosis: A Systematic Review and Meta‐Analysis of Over 5 Million Patients Across Different Clinical Settings
por: Vasileios Lekakis, et al.
Publicado: (2024)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
por: Xiao‐Dong Zhou, et al.
Publicado: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
por: Kaleb Tesfai, et al.
Publicado: (2025)

Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia—Results of a Post Hoc Analysis of the Phase 3 PALISADE Study
por: Rohit Loomba, et al.
Publicado: (2026)

Letter: Resmetirom for treatment of MASH with children and adolescents
por: Yong‐Hai Zhou, et al.
Publicado: (2024)

Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin
por: Gustavo Ayares, et al.
Publicado: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
por: Nobuharu Tamaki, et al.
Publicado: (2025)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
por: Nobuharu Tamaki, et al.
Publicado: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
por: Nobuharu Tamaki, et al.
Publicado: (2024)